Gabery, Sanaz

Semaglutide lowers body weight in rodents via distributed neural pathways.

Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 717

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial

Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 126

Integrated brain atlas for unbiased mapping of nervous system effects following liraglutide treatment

Salinas, C. B. G., Lu, T. T.-H., Gabery, S., Marstal, K., Alanentalo, T., Mercer, A. J., Cornea, A., Conradsen, K., Hecksher-Sørensen, J., Dahl, A. B., et al. (2018) · Scientific Reports

Cell Image Analysis TechniquesNeuroscience and Neuropharmacology Research

Cited by 95

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial

Gasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 46

Microstructural white matter alterations and hippocampal volumes are associated with cognitive deficits in craniopharyngioma

Fjalldal, S., Follin, C., Svärd, D., Rylander, L., Gabery, S., Petersén, Å., van Westen, D., Sundgren, P. C., Björkman-Burtscher, I. M., Lätt, J., et al. (2018) · European Journal of Endocrinology

Pituitary Gland Disorders and TreatmentsAdvanced Neuroimaging Techniques and Applications

Cited by 31